(2021). Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer.
Chicago Style Citation"Correction: Safety of Immune Checkpoint Inhibitor Rechallenge After Discontinuation for Grade ≥2 Immune-related Adverse Events in Patients With Cancer." J Immunother Cancer 2021.
MLA Citation"Correction: Safety of Immune Checkpoint Inhibitor Rechallenge After Discontinuation for Grade ≥2 Immune-related Adverse Events in Patients With Cancer." J Immunother Cancer 2021.
Warning: These citations may not always be 100% accurate.